Gout is linked to higher amputation risk in type 2 diabetes

Lower-limb amputation is one of the most feared complications of diabetes, and most cases begin with a foot ulcer that will not heal [s2]. The standard risk factors are well known: poor circulation, nerve damage, and prior ulceration. A study published on 3 November in Diabetologia points to one that is rarely counted — gout [s1].

What the study did

Researchers ran a nationwide, register-based case-control study among 601,541 individuals with type 2 diabetes [s1]. From that population they identified 4912 people who had undergone a lower-extremity amputation and matched them to 39,101 control participants of the same age and sex who had not [s1]. Gout exposure was determined from ICD-10 diagnostic codes and Anatomical Therapeutic Chemical codes for urate-lowering therapy — in other words, a recorded diagnosis or a prescription for gout treatment [s1]. Associations were estimated with conditional logistic regression, adjusted for diabetes duration, peripheral arterial disease, prior myocardial infarction, and late diabetes complications [s1].

The design matters for interpretation. A case-control study compares people who already have the outcome against those who do not, which is efficient for a relatively rare event like amputation but cannot establish cause. It can show that gout and amputation travel together after accounting for the obvious confounders; it cannot prove that treating gout would lower amputation risk.

The numbers

Before adjustment, gout was associated with an odds ratio of 1.85 (95% CI 1.69–2.02) for lower-extremity amputation [s1]. After full adjustment for diabetes duration, peripheral arterial disease, prior heart attack, and late complications, the association shrank but remained clearly significant: an odds ratio of 1.53 (95% CI 1.37–1.69) [s1].

The study also looked at where on the limb the amputations occurred, and found a significant trend across levels (p=0.03) [s1]. The association was present at every level but tended to be stronger at more distal — that is, further from the trunk — sites. The adjusted odds ratio was 1.37 (95% CI 1.12–1.68) for above-knee amputations, rising to 1.65 (95% CI 1.32–2.05) for toe amputations [s1]. The investigators note that although the trend was significant, the individual amputation levels did not differ significantly from one another, so the gradient should be read as a pattern rather than a sharp distinction [s1].

The adjustment set is worth naming, because it is what separates this from a simpler correlation. Peripheral arterial disease and long diabetes duration are themselves powerful drivers of amputation, and they are more common in people with gout; by conditioning on them, along with prior myocardial infarction and late diabetes complications, the analysis strips out the most obvious alternative explanations [s1]. That the odds ratio survives at 1.53 after all of that is the core of the claim [s1].

Why the distal signal is biologically plausible

The toe finding fits what is known about gout. Gout's crystals and inflammation have a long-standing predilection for the small joints of the foot — the big toe is the classic first site — and that localised inflammation, layered onto the poor circulation and neuropathy of diabetes, is a plausible route to tissue breakdown at exactly the sites most prone to it [s1]. The drop in the odds ratio after adjustment, from 1.85 to 1.53, also tells a story: some of the raw association runs through shared risk factors like peripheral arterial disease, but a substantial independent signal remains [s1].

What it means in practice

The clinical reading is modest and specific. Gout appears to be an independent marker of amputation risk in type 2 diabetes, which argues for counting it among the things clinicians weigh when assessing a patient's feet [s1]. Diabetes foot-care guidelines already stress regular risk stratification and early attention to the small lesions that precede amputation [s2]; this study suggests coexisting gout is a reason to look harder, not a new treatment in itself.

What it does not show is that lowering urate reduces amputations. That would require a different study design, and the register's reliance on diagnostic and prescription codes means some gout — undiagnosed or untreated — was likely missed, which tends to blur rather than manufacture an association [s1].

What to watch

The useful next question is whether the people with both conditions who are treated to urate target fare better than those who are not. Until that is tested, the finding stands as a flag: in a very large national population, gout and lower-limb amputation in type 2 diabetes are linked beyond what the usual risk factors explain [s1].

This article is informational and does not constitute medical advice.